EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Senhwa Biosciences, Inc. (6492) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Senhwa Biosciences, Inc. TWD 6.31, price TWD 34.40, upside -81.7%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW

SB Thin data Sep 24, 2026

Senhwa Biosciences, Inc.

6492 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 6.31 TWD · Strongly overvalued (−81.7%)
!Quality 44/100
!Expensive Growth (revenue 3y +2.3 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Senhwa Biosciences, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

203.50 TWD 28.90 TWD Fair Value 6.31 TWD May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 28.90 TWD – 203.50 TWD · fair‑value band 4.17 TWD – 7.89 TWD · the 34.40 TWD price screens above the 6.31 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Senhwa Biosciences in your weekly email

Every Wednesday you see whether Senhwa Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients.

Show more

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.

Stock analysis

Senhwa Biosciences, Inc. (6492) currently trades at 34.40 TWD, while our model-based Fair Value estimate is 6.31 TWD, 81.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 4.17 TWD (bear) to 7.89 TWD (bull), the price of 34.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Senhwa Biosciences, Inc. reported revenue of 1.1M TWD in FY2025 versus 550K TWD in FY2021, a compound +18.1%/yr. Reported net income was −265M TWD in FY2025.

Key figures

Market cap 4.0B TWD (≈ $126M) · EPS (TTM) −3.27 TWD · Return on equity −39.0% · Return on assets (EBIT) −24.8% · Operating margin −35,328% · Revenue (TTM) 1.1M TWD · Revenue growth (YoY) −4.0% · Free cash flow −249M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 47% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −82%, 6492 screens richer than that median.

Fair Value models

Bear 4.17 TWD Fair Value 6.31 TWD Bull 7.89 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3.33 TWD 4.46 TWD 6.65 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 3.33 TWD 4.46 TWD 6.65 TWD 54

Open the full fair value analysis →

Notify me when 6492 reaches fair value

Put 6492 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 46 · Market factors (momentum, volatility) 27

Profitability 0
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−62,966.5% (2021) → −26,005.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6492 screens overvalued: fair value 82% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Senhwa Biosciences, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −81.7% · Bottom 25%
Profitability
Return on assets −23.6% · Below median
Growth and dividend
Revenue growth −4.0% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.16× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Senhwa Biosciences, Inc. · Fair Value
6.31 TWD −82%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Senhwa Biosciences, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6492

Frequently asked questions

Is Senhwa Biosciences, Inc. (6492) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6.31 TWD versus a price of 34.40 TWD, about −82% upside (overvalued).
What is the fair value of 6492?
Our model-based fair value for Senhwa Biosciences, Inc. is 6.31 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 34.40 TWD.
What is the quality score of 6492?
Senhwa Biosciences, Inc. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Senhwa Biosciences, Inc. (6492)?
Our model-based price target is the fair value of 6.31 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 4.17 TWD, optimistic scenario 7.89 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Senhwa Biosciences, Inc. stock forecast for 2026?
Our models put fair value at 6.31 TWD, about −82% upside versus a price of 34.40 TWD (overvalued). Cautious scenario 4.17 TWD, optimistic scenario 7.89 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Senhwa Biosciences, Inc. (6492)?
Senhwa Biosciences, Inc. reported trailing-twelve-month revenue of about 1.1M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Senhwa Biosciences, Inc. (6492)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Senhwa Biosciences, Inc. it is 6.31 TWD per share (as of Sep 24, 2026), against a price of 34.40 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Senhwa Biosciences, Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6492 trades above its calculated fair value: price 34.40 TWD, fair value 6.31 TWD, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6492?
No. The price is what the market pays today (34.40 TWD); the fair value is what the company's own numbers justify (6.31 TWD). For Senhwa Biosciences, Inc. the two are 28.09 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Senhwa Biosciences, Inc. worth?
The market values Senhwa Biosciences, Inc. at about 4.0B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 34.40 TWD; our models calculate a fair value of 6.31 TWD per share.
What do the bullish and bearish scenarios say about 6492?
Our models span a range for Senhwa Biosciences, Inc.: cautious scenario 4.17 TWD, base 6.31 TWD, optimistic 7.89 TWD per share (as of Sep 24, 2026, price 34.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Senhwa Biosciences, Inc. (6492)?
Balance-sheet figures for Senhwa Biosciences, Inc. (as of Sep 24, 2026): return on equity −39.0%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 6492 from its 52-week high?
Senhwa Biosciences, Inc. trades at 34.40 TWD, about 47% below its 52-week high of 65.50 TWD and 3% above the low of 33.30 TWD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 6.31 TWD is for.
Which stocks are comparable to Senhwa Biosciences, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Senhwa Biosciences, Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 34.40 TWD, calculated fair value 6.31 TWD (−82%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6492 calculated?
We run Senhwa Biosciences, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6.31 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Senhwa Biosciences, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Senhwa Biosciences, Inc. (6492)?
The closing price on Oct 2, 2026 was 34.40 TWD. Our model-based fair value is 6.31 TWD, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Senhwa Biosciences, Inc. right now?
The price sits above even our optimistic bull case (7.89 TWD). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (4.17 TWD to 7.89 TWD) leaves room in how you read the outcome.

Key figures of Senhwa Biosciences, Inc.

How large is the market capitalisation of Senhwa Biosciences, Inc. (6492)?
The market capitalisation of Senhwa Biosciences, Inc. is 4.0B TWD (≈ $126M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Senhwa Biosciences, Inc. (6492)?
Earnings per share at Senhwa Biosciences, Inc. are −3.27 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Senhwa Biosciences, Inc. (6492)?
The return on equity (ROE) of Senhwa Biosciences, Inc. is −39.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Senhwa Biosciences, Inc. (6492)?
On an EBIT basis the return on assets of Senhwa Biosciences, Inc. is −24.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Senhwa Biosciences, Inc. (6492)?
The operating margin of Senhwa Biosciences, Inc. is −35,328% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Senhwa Biosciences, Inc. (6492)?
Revenue at Senhwa Biosciences, Inc. is growing −4.0% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Senhwa Biosciences, Inc. (6492) generate?
The free cash flow of Senhwa Biosciences, Inc. is −249M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Senhwa Biosciences, Inc. in the live analysis

One click puts Senhwa Biosciences, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.